Evidence map›Paper›PMID 41411610›Full record

ArticleJCO precision oncology2025

Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study.

Nina U Gelineau, Lieke M J van Zogchel, Boris De Carolis, Esther M van Wezel, Lily Zappeij-Kannegieter, Ahmad Javadi, Roswitha Schumacher-Kuckelkorn, Thorsten Simon, Frank Berthold, Max M van Noesel and 5 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nina U GelineauPrincess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands.ORCID 0009-0000-0348-8724
Lieke M J van ZogchelPrincess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands.ORCID 0000-0003-3557-7195
Boris De CarolisDepartment of Pediatric Hematology and Oncology, Children's Hospital-University of Cologne, Cologne, Germany.
Esther M van WezelDepartment of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory of the AMC-University of Amsterdam, Amsterdam, the Netherlands.
Lily Zappeij-KannegieterDepartment of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory of the AMC-University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-5493-5149
Ahmad JavadiDepartment of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory of the AMC-University of Amsterdam, Amsterdam, the Netherlands.
Roswitha Schumacher-KuckelkornDepartment of Pediatric Hematology and Oncology, Children's Hospital-University of Cologne, Cologne, Germany.
Thorsten SimonDepartment of Pediatric Hematology and Oncology, Children's Hospital-University of Cologne, Cologne, Germany.ORCID 0000-0002-3425-8451
Frank BertholdDepartment of Pediatric Hematology and Oncology, Children's Hospital-University of Cologne, Cologne, Germany.
Max M van NoeselPrincess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands.ORCID 0000-0003-0503-5838
Marta FioccoPrincess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands.ORCID 0000-0001-5588-0277
Janine StutterheimPrincess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands.ORCID 0000-0002-9828-0834
C Ellen van der SchootDepartment of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory of the AMC-University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-8065-3540
Barbara HeroDepartment of Pediatric Hematology and Oncology, Children's Hospital-University of Cologne, Cologne, Germany.ORCID 0000-0003-4129-890X
Godelieve A M TytgatPrincess Máxima Center for Pediatric Oncology, Research, Utrecht, the Netherlands.ORCID 0000-0003-4452-0748

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAbout 60% of patients with high-risk neuroblastoma relapse. Specific mRNA detection in bone marrow (BM) by reverse transcriptase quantitative PCR (RT-qPCR) is associated with survival outcomes. Peripheral blood (PB) sampling is less invasive. Therefore, we prospectively validated an RT-qPCR panel of neuroblastoma mRNA in PB of patients with high-risk neuroblastoma, treated in NB2004-HR (GPOH) and NBL2009 (DCOG).

methodsFrom 312 patients, 634 PB samples were prospectively collected (2009-2017) at diagnosis, after two cycles and end-of-induction therapy. RT-qPCR was performed using our panel of neuroblastoma mRNA markers:

resultsClear correlation between calculated infiltration by neuroblastoma mRNA expression in PB and BM was seen at diagnosis (

conclusionPB infiltration is associated with EFS and OS at diagnosis; it is also significantly associated with survival outcomes of patients with ≥10% BM infiltration at diagnosis. During follow-up, neuroblastoma mRNA detection in PB can be of added value, when BM analysis is not possible.

Indexed as

Neoplasm, ResidualNeuroblastomaBiomarkers, TumorChildChild, PreschoolFemaleHumansInfantMaleProspective StudiesRNA, MessengerBiomarkers, TumorRNA, Messenger

Identifiers

PMID41411610
PMCPMC12721697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.